Table 2.
Patient characteristics by dose level.
| Dose Level | 0.015 mg/kg/dose | 0.040 mg/kg/dose | 0.080 mg/kg/dose | Retreatment |
|---|---|---|---|---|
| Subjects, n | 4 | 16 | 6 | 3 |
| Age, y, Median (Range) | 65 (50 - 79) | 51 (27 - 72) | 58 (53 - 65) | 45 (27 - 47) |
| Gender, M:F, n | 2: 2 | 10: 6 | 5:1 | |
| Race, n (%) | ||||
| - Caucasian | 4 (100%) | 15 (94%) | 6 (100%) | 3 (100%) |
| - Black, African/American | 1 (6%) | |||
| ECOG Performance Status, n (%) | ||||
| 0 | 3 (75%) | 10 (63%) | 5 (83%) | 2 (67%) |
| 1 | 1 (25%) | 6 (38%) | 1 (17%) | 1 (33%) |
| Tumor Type (n) | Melanoma (1), renal cell carcinoma (1), colon cancer (1), neuroendocrine cancer (1) | Melanoma (6), renal cell carcinoma (4), prostate cancer (2), transitional cell carcinoma (1), collecting duct renal cancer (1), Hodgkin's lymphoma (1), head and neck cancer (1) | Melanoma (3), renal cell carcinoma (3) | Melanoma (1), collecting duct renal cancer (1), head and neck cancer (1) |
| Disease Stage, n (%) | ||||
| III | 1 (25%) | 2 (13%) | 1 (17%) | 1 (33%) |
| IV | 3 (75%) | 14 (88%) | 5 (83%) | 2 (67%) |